TrialRheumatology (Oxford, England)2018

Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis.

Michael B Arnold et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.